NCT07032272View on ClinicalTrials.gov

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 23, 2025

Primary Completion Date

November 21, 2025

Study Completion Date

November 24, 2025

Conditions
Autoimmune and Chronic Inflammatory Diseases
Interventions
DRUG

remibrutinib

Tablet with oral route of administration

Trial Locations (4)

32809

RECRUITING

Orlando Clinical Research Center, Orlando

33014

RECRUITING

Panax Clinical Research, Miami Lakes

33614

RECRUITING

Genesis Clinical Research, Tampa

33014-3616

RECRUITING

Clinical Pharmacology of Miami LLC, Miami

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY